Not Every Colposcopy Referral Carries the Same Risk

A German registry of 12,311 diagnostic colposcopy referrals found striking differences in CIN3+ detection across high-grade cytology, ASC-H, low-grade abnormalities, and persistent HPV with normal cytology.

Two patients can walk into the same colposcopy clinic on the same morning with the same phrase on their appointment record:

abnormal cervical screening.

Their underlying likelihood of finding CIN3+, however, may be very different.

One patient may have persistent high-risk HPV with normal cytology. Another may have HSIL. A third may have ASC-H, where high-grade disease cannot be excluded.

All deserve appropriate assessment. But placing them into a single “HPV-positive” or “colposcopy referral” category hides clinically useful information.

A 2026 German registry study involving 12,311 patients referred for diagnostic colposcopy makes that difference unusually visible. The study examined CIN3+ detection across several referral categories within Germany's organized cervical cancer screening program.

The range was substantial: approximately 6–7% in persistent HPV with normal cytology and 63.3% in the study's severe-HSIL referral category.

That spread is more useful than any single percentage.

It shows why a colposcopy referral should be interpreted in context before the examination even begins.

Why Colposcopy Is Moving Toward Risk-Based Decisions

Modern cervical screening increasingly separates two questions:

What did the screening test show?

and

What does that result mean for this patient's likelihood of CIN3+?

The two are related, but they are not interchangeable.

The ASCCP risk-based management framework is a clear example. Management is based on a combination of current HPV/cytology results, previous screening history, previous biopsy results, and other relevant factors rather than on one test result in isolation. The guidelines explicitly moved from result-based algorithms toward risk-based management.

Germany uses a different national screening algorithm, so the German registry percentages should not be imported directly into another country's management guidelines.

The broader principle is still useful:

a referral result carries context; it is not a universal risk estimate by itself.

What the 12,311-Patient Registry Examined

The registry included patients presenting for diagnostic colposcopy under Germany's organized cervical screening algorithm.

The study population included several distinct referral groups:

• persistent HPV with normal cytology;

• ASC-US;

• ASC-H;

• LSIL;

• moderate-grade HSIL;

• severe-grade HSIL;

• cytology suspicious for invasion.

That diversity is what makes the dataset clinically interesting.

Instead of asking how often CIN3+ appears across “all colposcopy patients,” it allows us to see how detection changes according to the abnormality that triggered referral.

CIN3+ Detection Varied Sharply by Referral Category

The corrected study reported:

Important context: these are CIN3+ detection rates in a selected German diagnostic-colposcopy population. Referral categories are reported using the study's English terminology derived from Germany's Munich Nomenclature III screening system and should not be assumed to map directly onto every national cytology classification or individual patient's risk.

The pattern nevertheless matters.

A patient referred after severe high-grade cytology reached colposcopy from a very different starting point than someone referred because of persistent HPV with normal cytology.

Both may undergo colposcopy.

They should not be thought of as clinically identical referrals.

ASC-H Shows Why a Percentage Is Not the Whole Story

ASC-H deserves particular attention.

The German registry found CIN3+ in 27.6% of ASC-H referrals, close to the 27.4% reported in the moderate-HSIL group. Seven cervical carcinomas were also identified in the ASC-H group.

That fits with the broader clinical concern surrounding ASC-H.

ASCCP recommends colposcopy for ASC-H regardless of HPV result because cancer risk can remain clinically important even when CIN3+ estimates differ by HPV status.

Risk stratification therefore cannot be reduced to ranking a few percentages from highest to lowest.

The nature of the abnormality still matters.

“HPV Positive” Is Not One Risk Category

HPV testing is central to modern cervical screening, but HPV positive is not a complete clinical description.

Risk can change with:

• HPV genotype;

• persistence;

• cytology;

• previous HPV and cytology results;

• previous biopsy or treatment history;

• age and broader clinical context.

This is why risk-based guidelines do not treat every HPV-positive result as an automatic indication for identical management. In the ASCCP framework, the same current screening result can lead to different recommendations depending on prior history.

A patient with high-risk HPV and HSIL cytology is therefore not clinically equivalent to a patient with persistent HPV and normal cytology.

The label “HPV positive” alone does not tell the whole story.

Persistent HPV With Normal Cytology: Lower Detection, Not Zero

Persistent HPV with normal cytology is particularly useful for illustrating this point.

In the German registry, CIN3+ was detected in approximately 6–7% of the two persistent-HPV/normal-cytology referral groups.

That is far below the 63.3% observed in the severe-HSIL group.

It is also not zero.

The correct conclusion is therefore not:

Persistent HPV with normal cytology always requires immediate colposcopy.

National screening programs use different referral thresholds, HPV-genotyping strategies, and follow-up intervals.

A safer conclusion is:

persistent HPV with normal cytology represents a clinically different risk context from high-grade cytology, and management needs to follow the patient's full history and the applicable national guideline.

Risk Stratification Also Affects Colposcopy Capacity

There is an operational side to this discussion.

HPV-based screening can increase the number of people entering triage pathways and, depending on the screening program, increase colposcopy referrals.

That matters because colposcopy capacity is finite.

A Dutch study published in 2024 evaluated HPV-genotyping strategies specifically to determine whether referrals could be concentrated more efficiently among people at higher CIN3+ risk. The authors concluded that HPV-based screening can become more efficient when immediate colposcopy referral is limited to higher-risk groups.

For hospitals, risk stratification affects more than the referral letter.

A colposcopy service must coordinate:

• high-risk referrals;

• lower-risk referrals;

• biopsies;

• pathology results;

• surveillance;

• follow-up;

• documentation.

Better stratification does not make colposcopy less important.

It helps make the service more deliberate.

The Referral Context Should Reach the Colposcopy Room

A good colposcopy workflow starts before cervical visualization.

The clinician should have access to the information that brought the patient there:

• cytology;

• HPV status;

• genotype, where available;

• persistence;

• previous screening results;

• previous histology;

• previous cervical treatment.

This information changes the context in which the examination is interpreted.

The same visual finding is not being assessed in the same pre-test setting when one patient arrives after persistent HPV/NILM and another after high-grade cytology.

The colposcope does not calculate that risk.

The clinical pathway does.

What Clinics Need From a Modern Colposcopy Workflow

This distinction also matters when clinics evaluate colposcopy equipment.

A higher-resolution camera does not automatically produce better CIN3+ detection, and the German registry did not test whether one imaging specification improves high-grade lesion detection.

The equipment has a different job.

Once the patient reaches colposcopy, the system should help the clinical team examine, document, review, and communicate what they see.

Useful workflow capabilities include:

• stable cervical visualization;

• image and video documentation;

• recording lesion appearance;

• documenting biopsy locations;

• retaining patient examination records;

• reviewing previous images;

• producing consistent clinical reports.

KernelMed's GN-500 Digital Video Colposcope and GN-100BII 4K Optical Video Colposcope represent two different professional approaches to this workflow.

The GN-500 emphasizes digital imaging, image/video capture, and clinical documentation, while the GN-100BII combines optical binocular observation with digital imaging capability.

Neither device determines whether a patient belongs to a high-risk referral group.

That remains the responsibility of validated screening algorithms and clinical judgment.

The role of the colposcopy system is to support what happens after that risk assessment brings the patient into the examination room.

What 12,311 Referrals Really Tell Us

The most useful result from this registry may not be 63.3%, 27.6%, or 6.3%.

It may be the distance between those numbers.

All 12,311 patients reached diagnostic colposcopy.

They did not arrive with the same clinical probability of CIN3+.

High-grade cytology, ASC-H, low-grade abnormalities, and persistent HPV with normal cytology represent different starting points in the diagnostic pathway.

That leads to a simple conclusion:

not every colposcopy referral carries the same underlying risk.

Colposcopy shows clinicians what is present at examination.

Risk stratification helps explain why the patient is there—and how much is already known before the examination begins.

FAQ

Does every HPV-positive patient need colposcopy?

No. Management depends on HPV genotype, cytology, persistence, previous screening history, and the applicable national guideline. Risk-based systems do not treat HPV positivity alone as a universal indication for identical management.

What does CIN3+ mean?

CIN3+ generally includes cervical intraepithelial neoplasia grade 3 and more severe diagnoses, including adenocarcinoma in situ and invasive cervical cancer in commonly used risk-management frameworks.

What was the CIN3+ detection rate after severe-HSIL referral in the German registry?

The study reported CIN3+ in 63.3% of referrals classified as severe HSIL and 27.4% in its moderate-HSIL category. These are detection rates from this German referral population, not universal individual risk estimates.

What was the CIN3+ detection rate in ASC-H?

CIN3+ was detected in 27.6% of ASC-H referrals. Seven cervical carcinomas were reported in this group.

Can persistent HPV with normal cytology still be associated with CIN3+?

Yes. Approximately 6–7% of the persistent-HPV/normal-cytology referral groups in this registry were diagnosed with CIN3+. Management still depends on the screening program and the patient's complete risk profile.

Does a high-resolution colposcope increase CIN3+ detection?

This registry did not study that question. High-quality imaging supports visualization and documentation, but CIN3+ detection depends on the full clinical pathway, including screening context, colposcopic assessment, biopsy when indicated, and histopathology.

References

1. Henes M, et al. Registry Study of the Working Group on Cervical Pathology and Colposcopy (AGCPC)... Evaluation of over 10000 Patients. 2026.
   PubMed record

2. Correction to the AGCPC Registry Study. 2026. The correction relates to the original article and has been formally indexed as a published erratum.
   Published correction

3. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors.
   Full guideline

4. Kroon KR, et al. Colposcopy Referral and CIN3+ Risk of Human Papillomavirus Genotyping Strategies in Cervical Cancer Screening. 2024.
   Study page